We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.62%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.43B
AUM Growth
+$108M
Cap. Flow
-$133M
Cap. Flow %
-9.27%
Top 10 Hldgs %
45.41%
Holding
87
New
7
Increased
18
Reduced
17
Closed
14

Top Buys

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$37.2M
2
APLS
Apellis Pharmaceuticals
APLS
+$31.2M
3
ACLX
Arcellx
ACLX
+$29.2M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$22.7M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20.3M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$187M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$35.3M
3
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$21.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.3M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
76
Axsome Therapeutics
AXSM
$10.9B
– –
-205,000
Closed -$7.85M
CLDX icon
77
Celldex Therapeutics
CLDX
$3.28B
– –
-200,000
Closed -$5.39M
KZR
78
DELISTED
Kezar Life Sciences
KZR
– –
-120,000
Closed -$9.92M
MGTX icon
79
MeiraGTx Holdings
MGTX
$1.21B
– –
-150,000
Closed -$1.14M
SWTX
80
DELISTED
SpringWorks Therapeutics
SWTX
– –
-475,000
Closed -$11.7M
XBI icon
81
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-450,000
Closed -$33.4M
ITCI
82
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-275,000
Closed -$15.7M
RCOR
83
DELISTED
Renovacor, Inc.
RCOR
– –
-500,000
Closed -$1.01M
CCXI
84
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-1,425,000
Closed -$35.3M
FMTX
85
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-3,172,204
Closed -$21.9M
TPTX
86
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-2,484,220
Closed -$187M
HZNP
87
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-267,500
Closed -$21.3M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Cormorant Asset Management held 87 positions worth $1.43B, up 8.2% from $1.32B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $133M in Q3 2022, closing 14 positions and reducing 17 holdings. Its most notable exit was Turning Point Therapeutics, Inc. Common Stock, an estimated $187M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Arcutis Biotherapeutics worth $19.1M.

  • Cormorant Asset Management's largest Q3 2022 buy was Arcutis Biotherapeutics: 1,000,000 shares worth $19.1M.
  • Cormorant Asset Management added most to Gossamer Bio in Q3 2022, an estimated $37.2M increase.
  • Cormorant Asset Management's biggest Q3 2022 reduction was Design Therapeutics, cutting an estimated $9.95M.
  • Cormorant Asset Management fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $187M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $1.43B portfolio in Q3 2022.
  • Cormorant Asset Management opened 7 new positions and closed 14 in Q3 2022.
  • Cormorant Asset Management's portfolio value rose 8.2% quarter-over-quarter to $1.43B.

Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.